# An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

> **NCT01296386** · PHASE1 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 82 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **BIOLOGICAL:** IC84

## Key facts

- **NCT ID:** NCT01296386
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01296386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01296386, "An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01296386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*